FDA Warns on AbbVie's Hepatitis C Treatments - Nasdaq

The U.S. Food and Drug Administration warned that AbbVie Inc.'s new hepatitis C treatments may cause serious liver harm among patients with underlying liver disease—a blow to some of a new generation of drugs seen as a big advance for hepatitis patients.

The FDA said in a safety alert Thursday it has received reports of liver failure and complications in patients with cirrhosis, or scarring of the liver, who were taking the AbbVie medicines Viekira Pak and Technivie.

Read Full Story